PAINWeek Abstract Book 2018

Excerpt : “Misuse/abuse of prescription opioids has been recognized as a public health crisis by the U.S. Food and Drug Administration (FDA) and the FDA’s Opioid Action Plan recognizes abuse-deterrent (AD) formulations of opioids as critical to mitigating opioid misuse/abuse. Morphine abuse-deterrent, extended-release injection-molded tablets (ADER-IMT) developed to resist common and rigorous forms of physical and chemical manipulation, were recently approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. There is significant interest in evaluating the impact of AD opioids on ‘real-world outcomes.’ We used a harm reduction model-based approach to investigate the extent of the potential to reduce opioid misuse/abuse-related events by simulating, over 5 years, the replacement of non-abuse deterrent morphine formulations with morphine ADER-IMT. …”

…read more, download the PAINWeek Abstract Book 2018 PDF here

Originally published : http://dx.doi.org/10.1080/00325481.2017.1367065

       

About The Author

iPharmaTrials.com

Twitter @iPharmaTrials // International Pharma Trials

iPHARMA TRIALS

 

New York, USA
Telephone : 718-332-7878
rkrishna -AT- ipharmatrials.com
.. replace -AT- with @

United Kingdom
The Studio/East Batterlaw Farm
Seaham SR7 8RP

Corporation Registration Address:
330 Thornton Road Englewood NJ 07631

@iPharmaTrials